Zacks Investment Research·Sep 14, 2026
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
AtriCure is transitioning from a growth-focused medical device maker to a profitable operator, with Q2 2026 revenue up 12.8% YoY to $153.6M and operating income swinging to $9.7M from a -$6.2M loss a year earlier. The company's gross margin expanded to 77.2%, ...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 23, 2026 | $0.18+10878.4% vs -$0.00 | $154M+1.2% vs $152M |
Q2 2026 May 5, 2026 | $0.00+103.1% vs -$0.07 | $141M+1.1% vs $140M |
Q1 2026 Feb 17, 2026 | $0.06+249.9% vs -$0.04 | $141M+0.6% vs $140M |
Q4 2025 Oct 29, 2025 | -$0.01+90.9% vs -$0.11 | $134M-4.4% vs $141M |
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Benchmark ATRC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AtriCure, Inc. (ATRC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $58.83 | $2.99B | -245.13 | 14.88% | -2.14% | -2.4% | — | |
| $16.67 | $1.93B | -13.66 | 8.28% | -21.25% | -44% | — | |
| $110.53 | $3.63B | -79.52 | 26.24% | -1.69% | -8.97% | — | |
| $0.43 | $24.07M | -0.70 | — | — | -686.78% | — | |
| $103.73 | $180.68B | 27.88 | 5.67% | 13.91% | 12.09% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — |
AtriCure, Inc. (ATRC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AtriCure, Inc. (ATRC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 23, 2026·SEC
May 19, 2026·SEC
May 5, 2026·SEC
Get notified when ATRC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AtriCure, Inc. (ATRC) stock FAQ — growth, dividends, profitability & financials explained
AtriCure, Inc. (ATRC) reported $569.6M in revenue for fiscal year 2025. This represents a 2873% increase from $19.2M in 2004.
AtriCure, Inc. (ATRC) grew revenue by 14.9% over the past year. This is steady growth.
Yes, AtriCure, Inc. (ATRC) is profitable, generating $10.6M in net income for fiscal year 2025 (-2.1% net margin).
AtriCure, Inc. (ATRC) has a return on equity (ROE) of -2.4%. Negative ROE indicates the company is unprofitable.
AtriCure, Inc. (ATRC) generated $58.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
